Nanobody-functionalized liposomal doxorubicin: A novel strategy for angiogenesis suppression via VEGFR2 targeting
This designed drug delivery system worked as strong anticancer and angiogenesis suppression agent <i>ex-vitro</i> angiogenesis model via VEGFR2 targeting.
Authors
- Hamidreza Kheiri-Manjili
- Davoud Ahmadvand (ORCID: https://orcid.org/0000-0002-5611-5056)
- Azadeh Ghaffari (ORCID: https://orcid.org/0000-0002-4464-9093)
- Fahimeh Hajiahmadi
- Cobra Moradian (ORCID: https://orcid.org/0000-0002-3948-4642)
- Mahdi Behdani (ORCID: https://orcid.org/0000-0002-4839-5123)
- Vahideh Farzam Rad (ORCID: https://orcid.org/0000-0002-2769-0713)
- Aezam Akbari (ORCID: https://orcid.org/0009-0004-5102-5977)
Institutions
- Zanjan University of Medical Sciences (IR)
- Pasteur Institute of Iran (IR)
- Institute for Advanced Studies in Basic Sciences (IR)
- Iran University of Medical Sciences (IR)
- University of California, San Francisco (US)
- Biotechnology Research Center (IR)
- University of Zanjan (IR)
Publication Details
- Journal
- Bioimpacts
- Published
- 2025-04-06
- DOI
- https://doi.org/10.34172/bi.30707
- Citations
- 2
- Primary Topic
- Nanoparticle-Based Drug Delivery
- Type
- article
- Field-Weighted Citation Impact
- 1.19
Funders
- Iran University of Medical Sciences
- Zanjan University of Medical Sciences
- University of Zanjan